Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q3 FY21 results · Oct–Dec 2020
Cohance Lifesciences reported revenue from operations of ₹274.93 crore and net profit of ₹113.63 crore for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 274.93 | — | — | 237.39 | +15.8% |
| Other income | 4.84 | — | — | 0.36 | 14x |
| Total income | 279.78 | — | — | 237.74 | +17.7% |
| Profit before share of associates & JVs and tax | 131.50 | — | — | 88.08 | +49.3% |
| Share of profit/(loss) of associates & JVs | 16.00 | — | 8.75 | ||
| Net profit for the period | 113.63 | — | — | 74.08 | +53.4% |
| EPS, basic (₹) | 4.46 | — | — | 2.91 | +53.3% |
| Net margin (%) | 41.3 | — | 31.2 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 274.93 | — | — | 237.39 | +15.8% |
| Other income | 4.84 | — | — | 0.36 | 14x |
| Total income | 279.78 | — | — | 237.74 | +17.7% |
| Profit before tax | 131.51 | — | — | 88.09 | +49.3% |
| Net profit for the period | 97.63 | — | — | 65.33 | +49.4% |
| EPS, basic (₹) | 3.84 | — | — | 2.57 | +49.4% |
| Net margin (%) | 35.5 | — | 27.5 |
Consolidated
- Filed with BSE
- 11 Feb 2021, 13:15 IST
- Board meeting
- 10 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2021, 13:15 IST
- Board meeting
- 10 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE